Literature DB >> 27602743

Perspective: The precision-oncology illusion.

Vinay Prasad1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27602743     DOI： 10.1038/537S63a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.

Authors:  Funda Meric-Bernstam; Lauren Brusco; Kenna Shaw; Chacha Horombe; Scott Kopetz; Michael A Davies; Mark Routbort; Sarina A Piha-Paul; Filip Janku; Naoto Ueno; David Hong; John De Groot; Vinod Ravi; Yisheng Li; Raja Luthra; Keyur Patel; Russell Broaddus; John Mendelsohn; Gordon B Mills
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

2.  Genome sequencing identifies a basis for everolimus sensitivity.

Authors:  Gopa Iyer; Aphrothiti J Hanrahan; Matthew I Milowsky; Hikmat Al-Ahmadie; Sasinya N Scott; Manickam Janakiraman; Mono Pirun; Chris Sander; Nicholas D Socci; Irina Ostrovnaya; Agnes Viale; Adriana Heguy; Luke Peng; Timothy A Chan; Bernard Bochner; Dean F Bajorin; Michael F Berger; Barry S Taylor; David B Solit
Journal:  Science       Date:  2012-08-23       Impact factor: 47.728

Review 3.  Characteristics of Exceptional or Super Responders to Cancer Drugs.

Authors:  Vinay Prasad; Andrae Vandross
Journal:  Mayo Clin Proc       Date:  2015-11-03       Impact factor: 7.616

4.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316

5.  Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

Authors:  Maria Schwaederle; Melissa Zhao; J Jack Lee; Vladimir Lazar; Brian Leyland-Jones; Richard L Schilsky; John Mendelsohn; Razelle Kurzrock
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777
  5 in total
  101 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  New strategies in esophageal carcinoma: promises and problems.

Authors:  Zhaohui Xiong; Jingxi He; Xiaoxin Luke Chen
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

3.  Molecular medicine: Precision oncology is not an illusion.

Authors:  Edward Abrahams; Stephen L Eck
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

4.  Debunking the Delusion That Precision Oncology Is an Illusion.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Oncologist       Date:  2017-05-26

Review 5.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

6.  Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics.

Authors:  Michael Q Ding; Lujia Chen; Gregory F Cooper; Jonathan D Young; Xinghua Lu
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

Review 7.  Finding the right balance between precision medicine and personalized care.

Authors:  Finlay A McAlister; Andreas Laupacis; Paul W Armstrong
Journal:  CMAJ       Date:  2017-08-21       Impact factor: 8.262

8.  Organoids lead the cancer attack.

Authors:  Amber R Smith; Calvin J Kuo
Journal:  Nat Med       Date:  2017-12-07       Impact factor: 53.440

Review 9.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

Review 10.  Circulating tumor cells and CDX models as a tool for preclinical drug development.

Authors:  Alice Lallo; Maximilian W Schenk; Kristopher K Frese; Fiona Blackhall; Caroline Dive
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.